129 related articles for article (PubMed ID: 17311867)
1. Morphoproteomic expression of H-ras (p21ras) correlates with serum monoclonal immunoglobulin reduction in multiple myeloma patients following pamidronate treatment.
Zhang PL; Quiery AT; Blasick TM; Brown RE
Ann Clin Lab Sci; 2007; 37(1):34-8. PubMed ID: 17311867
[TBL] [Abstract][Full Text] [Related]
2. [Analysis of monoclonal protein in 72 cases of multiple myeloma].
Yang JJ; Zhang GS; Chen XR
Hunan Yi Ke Da Xue Xue Bao; 2001 Apr; 26(2):152-4. PubMed ID: 12536652
[TBL] [Abstract][Full Text] [Related]
3. The effect of zoledronic acid on serum osteoprotegerin in early stage multiple myeloma.
Martini G; Gozzetti A; Gennari L; Avanzati A; Nuti R; Lauria F
Haematologica; 2006 Dec; 91(12):1720-1. PubMed ID: 17145616
[TBL] [Abstract][Full Text] [Related]
4. Anti-myeloma activity of pamidronate in vivo.
Dhodapkar MV; Singh J; Mehta J; Fassas A; Desikan KR; Perlman M; Munshi NC; Barlogie B
Br J Haematol; 1998 Nov; 103(2):530-2. PubMed ID: 9827929
[TBL] [Abstract][Full Text] [Related]
5. Maxilla osseus sequestre and oral exposure: effects of the treatment of multiple myeloma with bisphosphonates.
Lobato JV; Rodrigues JM; Cavaleiro MV; Lobato JM; Xavier L; Santos JD; Maurício AC
Acta Med Port; 2007; 20(2):185-92. PubMed ID: 17868526
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumor activity of pamidronate in human multiple myeloma.
Kondo H; Mori A
Leuk Lymphoma; 2002 Apr; 43(4):919-21. PubMed ID: 12153188
[TBL] [Abstract][Full Text] [Related]
7. Serum free light chains for monitoring multiple myeloma.
Mead GP; Carr-Smith HD; Drayson MT; Morgan GJ; Child JA; Bradwell AR
Br J Haematol; 2004 Aug; 126(3):348-54. PubMed ID: 15257706
[TBL] [Abstract][Full Text] [Related]
8. [Markedly elevated serum fructosamine in a non-diabetic patient with IgA-kappa type multiple myeloma].
Nakamura F; Kaimori M; Takaya H; Fujita K; Suzuki N; Sakurabayashi I; Yoshioka N
Rinsho Byori; 1996 Jan; 44(1):85-9. PubMed ID: 8691646
[TBL] [Abstract][Full Text] [Related]
9. Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma.
Abe Y; Muto M; Nieda M; Nakagawa Y; Nicol A; Kaneko T; Goto S; Yokokawa K; Suzuki K
Exp Hematol; 2009 Aug; 37(8):956-68. PubMed ID: 19409955
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of farnesyl protein transferase and P21ras memebrane association by d-limonene in human pancreas tumor cells in vitro.
Chen X; Yano Y; Hasuma T; Yoshimata T; Yinna W; Otani S
Chin Med Sci J; 1999 Sep; 14(3):138-44. PubMed ID: 12903812
[TBL] [Abstract][Full Text] [Related]
11. Global gene expression profiling unveils S100A8/A9 as candidate markers in H-ras-mediated human breast epithelial cell invasion.
Moon A; Yong HY; Song JI; Cukovic D; Salagrama S; Kaplan D; Putt D; Kim H; Dombkowski A; Kim HR
Mol Cancer Res; 2008 Oct; 6(10):1544-53. PubMed ID: 18922970
[TBL] [Abstract][Full Text] [Related]
12. Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma.
Gordon S; Helfrich MH; Sati HI; Greaves M; Ralston SH; Culligan DJ; Soutar RL; Rogers MJ
Br J Haematol; 2002 Nov; 119(2):475-83. PubMed ID: 12406088
[TBL] [Abstract][Full Text] [Related]
13. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates.
Aparicio A; Gardner A; Tu Y; Savage A; Berenson J; Lichtenstein A
Leukemia; 1998 Feb; 12(2):220-9. PubMed ID: 9519785
[TBL] [Abstract][Full Text] [Related]
14. Low IgE monoclonal gammopathy level in serum highlights 20-yr survival in a case of IgE multiple myeloma.
Hayes MJ; Carey JL; Krauss JC; Hedstrom DL; Gulbranson RL; Keren DF
Eur J Haematol; 2007 Apr; 78(4):353-7. PubMed ID: 17378894
[TBL] [Abstract][Full Text] [Related]
15. [Two cases of rheumatoid arthritis associated with IgA -type multiple myeloma].
Matsumori A; Nishiya K; Chijiwa T; Tahara K; Hosokawa T; Kumon Y; Hashimoto K; Ookubo S; Takatori K
Ryumachi; 2000 Feb; 40(1):26-31. PubMed ID: 10783663
[TBL] [Abstract][Full Text] [Related]
16. Acute phase reactants and clinical stages in multiple myeloma.
San Miguel J; Vicente V; Battle J; Hernandez F; Lopez Borrasca A
Neoplasma; 1981; 28(3):333-8. PubMed ID: 7290260
[TBL] [Abstract][Full Text] [Related]
17. Mesenchymal stromal cells revert multiple myeloma cells to less differentiated phenotype by the combined activities of adhesive interactions and interleukin-6.
Dezorella N; Pevsner-Fischer M; Deutsch V; Kay S; Baron S; Stern R; Tavor S; Nagler A; Naparstek E; Zipori D; Katz BZ
Exp Cell Res; 2009 Jul; 315(11):1904-13. PubMed ID: 19328780
[TBL] [Abstract][Full Text] [Related]
18. Pamidronate in the treatment of osteolytic bone lesions in multiple myeloma patients--the American experience.
Berenson J
Br J Clin Pract Suppl; 1996 Sep; 87():5-7; discussion 13-4. PubMed ID: 8995010
[No Abstract] [Full Text] [Related]
19. Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma.
Kaiser M; Mieth M; Liebisch P; Oberländer R; Rademacher J; Jakob C; Kleeberg L; Fleissner C; Braendle E; Peters M; Stover D; Sezer O; Heider U
Eur J Haematol; 2008 Jun; 80(6):490-4. PubMed ID: 18331598
[TBL] [Abstract][Full Text] [Related]
20. The effects of zoledronic acid on serum lipids in multiple myeloma patients.
Gozzetti A; Gennari L; Merlotti D; Salvadori S; De Paola V; Avanzati A; Franci B; Marchini E; Tozzi M; Campagna MS; Nuti R; Lauria F; Martini G
Calcif Tissue Int; 2008 Apr; 82(4):258-62. PubMed ID: 18418538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
